was characterized according to survival time, control of DM with respect to reduction in insulin requirements over time, and the incidence of presumed acute and late normal tissue adverse radiation effects.
| M A TE RI A L S A ND M E TH ODS

| Case selection
Cats with acromegaly that were treated with curative-intent SRT at the Colorado State University Veterinary Teaching Hospital between February 2008 and November 2016 were included in our study. Inclusion criteria were developed by T. Wormhoudt, K. Lunn, and S. LaRue and consisted of cats diagnosed with acromegaly and concurrent DM.
Medical records were reviewed and follow-up data was collected from referring veterinarians and clients regarding presenting clinical signs, clinical signs after treatment, prescribed insulin dose before and after treatment, thyroid hormone status, acute and late normal tissue adverse radiation effects, response to therapy and overall survival time.
Data was collected from staging diagnostic tests which were performed before radiation therapy, including CBC, serum biochemical profile, urinalysis, serum IGF-1 concentration, thoracic radiographs, echocardiogram, abdominal ultrasound examination, computed tomography (CT) examination and magnetic resonance imaging (MRI) when available.
| CT examination
Computed tomography examination was performed using either a Picker When obtaining CT images for radiation planning, all patients were placed in sternal recumbency in a foam trough with the forelimbs positioned caudally. Patients' heads were further immobilized using a previously described system including a carbon fiber stand, a fixed thermoplastic dental mold, and a facial mask ( Figure 1) . 22 A Styrofoam bead-style cushion was used to provide ventral support to the cervical region.
22
A non-contrast volumetric (helical) dataset was obtained through the skull. Omnipaque 350 (GE Healthcare, Princeton, New Jersey) contrast media then was injected IV (2.2 mL/kg) before the postcontrast series. Images were reconstructed at 2.0 mm contiguous intervals with a 512 matrix, using the smooth algorithm.
| Radiation treatment planning
Both the 2-mm precontrast and postcontrast CT scan were used for inverse treatment planning performed using a Varian Eclipse treatment planning system (Varian Medical Systems, Inc Palo Alto, California).
Organs at risk (OAR) and gross tumor volume (GTV) were identified and contoured. A 1-2 mm isotropic planned target volume (PTV) expansion encompassed the GTV to account for daily set-up positioning error. No clinical target volume was used. The OARs for the radiation treatment plans included brain, skin, palatine mucosa, ocular lenses, optic chiasm, pharynx, bone, esophagus, and cochlea. Normal brain tissue was defined as the contoured brain minus the GTV for radiation treatment planning. When MRI was available, the T1-weighted postcontrast was fused with the CT in the treatment planning software to aid in contouring of the tumor volumes.
Inverse-planning was employed using Eclipse planning software; all plans were designed using coplanar or noncoplanar, isocentrically placed 6 MV radiation beams. Radiation beams were modulated using sliding-window technique. The intent for each radiation plan was to deliver 100% of the radiation prescription to 99% of the GTV and 95%
of the PTV. The volume constraint for the brain in these plans was that no more than 1.0 cc of normal brain may receive 24Gy for 3 fractions and 27Gy for 4 fractions. Biological equivalent doses (BED) were calculated for comparison of plans based on the following formula:
where n is the number of fractions, d is the dose per fraction and the a/b was assumed to be 10 for a tumor.
Quality assurance (QA) was performed by gamma analysis using the Varian portal dosimetry system on individual fields. A minimum of 95% gamma for a 3 mm distance to agreement and a 3% absolute dose difference were defined as a passing QA score.
When retrospectively reviewing the radiation treatment plans, the following data was collected: dose to 99% of GTV, dose to 95% of PTV, maximum tumor dose, minimum tumor dose, mean doses to the PTV, conformity index (CI), and gradient index (GI). The GTV was recorded for each patient. Regarding radiation dose delivered to normal brain tissue, the dose of 1.0 cc of the normal brain was recorded.
The CI is a quantitative measurement evaluating the degree of conformity of the dose distribution to the size and shape of the target volume and can be calculated as CI 5 TV 
| Statistical analysis
Survival time was calculated as the time between the first day of treatment and death. Survival analysis was performed on an intent-to-treat basis; events included death of the patients. Cats were censored at the time of analysis if they were still alive or lost to follow-up. KaplanMeier survival curves were created depicting median survival time.
Continuous variables including age, weight, plasma IGF-1 concentrations, and GTV were evaluated for correlation using Pearson's correlation coefficient. The data was described using means, medians, and 95% confidence limits of means. A P-value of .05 was considered for statistical significance. The software SAS v9.4 (SAS Institute Inc, Cary, North Carolina) was used for all statistical analyses.
| RE SUL TS
| Patient population
Fifty-six cats with pituitary tumors were considered for our study from case reviews. Three cats with pituitary tumors not causing signs 
| Imaging findings
| Radiation treatment protocol
Several SRT treatment protocols were utilized to treat the cats, but the dose per fraction generally was escalated as we became more experienced with normal tissue tolerance. Forty-four cats received 8Gy over 3 consecutive days for a total of 24Gy. Five cats received 7Gy over 4 days for a total of 28Gy. Three cats received 6.75Gy over 4 consecutive days for a total of 27Gy. One patient received 18Gy in 3 fractions of 6Gy. One of the cats that received 24Gy over 3 fractions of 8Gy, was re-treated with a single fraction of 17Gy. Consecutive days are defined by a Monday-Friday schedule. The mean dose to 1 cc of normal brain for the patients that received 4 fractions of SRT was 22.6Gy (range, [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] . The mean dose to 1 cc of normal brain for the patients that received 3 fractions of SRT was 19.5Gy (range, [16] [17] [18] [19] [20] [21] [22] [23] [24] . The dose to 1 cc of normal brain for the patient that received a single fraction of 17Gy was 9.0Gy. Figure 2 presents a selected patient's dose volume histogram (DVH) and dose color wash from the treatment planning software. Dose refers to the radiation dose (in gray). CI 5 (prescription isodose volume)2/(total PTV volume) 3 (prescription isodose volume). The mean decrease in insulin was 72% (median, 86%; range, 250%-100%).
| Radiation-induced adverse effects
Acute radiation effects were reported in 10 cats (18%) during radiation treatment, including mental dullness, light sensitivity, or mydriasis. In all cases, these effects were treated with prednisolone (0.5-1 mg/kg q24h for 1-6 weeks) and resolved without complication. One cat lost vision 
| Necropsy findings
| D ISC USSION
Ours is the first study to evaluate the use of stereotactic radiation to treat pituitary tumors causing acromegaly in cats. The overall median survival time is longer than in other published studies evaluating conventionally fractionated, coarse fractionated and single fraction radiation treatments for acromegalic cats. Median survival in those studies ranged from 508 to 840 days, compared to 1072 days reported here. [6] [7] [8] [9] This information, along with data from humans, suggests that a higher dose per fraction may be more biologically effective for this tumor type. 24 In addition to longer overall survival time, a higher proportion of the patients in our study had a more favorable response in terms of control of their DM. Previous studies reported a decrease in
exogenous insulin requirements in 55%-92% of treated patients compared with 95% reported here. [6] [7] [8] [9] The information from our study is comparable to results of stereotactic radiosurgery for treatment of functional pituitary adenomas in humans. 24 In human patients, a single fraction of 35Gy resulted in shorter time to and higher rate of endocrine remission without an increase in radiation-induced adverse effects when compared to conventionally fractionated radiation. 24 In the previously described study, 70% of patients experienced endocrine remission with a median time of 17.7 months. Considering the improvement noted in our study and the reported human literature, evidence supports a higher dose per fraction to gain control of this disease.
The dose-limiting normal tissue in our study was the normal brain.
The goal of the Radiation Oncology Service at CSU is to keep 1.1 cc of normal brain under 24Gy for 3 fractions and under 27Gy for 4 fractions. 17 Assuring that the brain was within tolerance constraints took precedence over total radiation dosage administered to the tumor volumes. Late radiation effects to the brain are irreversible and frequently incompatible with good quality of life. Neurologic changes were noted in 7 patients at the time of euthanasia. No advanced imaging was performed on these patients to confirm tumor recurrence or suggest possible late radiation effects. Necropsy in 2 cases did not show changes in the brain outside of the pituitary gland.
The other OAR considered in our study included the optic chiasm.
Although the optic chiasm was consistently contoured in all patients treated, radiation dose to the tumor was not jeopardized to spare this tissue. Given the proximity of the optic chiasm to the sella turcica, in most cats the OAR dose was above the given constraint of 21Gy. 25 Owners were consistently warned about the potential of vision loss after radiation therapy given full dose to the optic chiasm in most patients. Despite this, only 1 patient reportedly lost vision in both eyes without development of cataracts 2.5 years after treatment. This finding was suspected to be a late radiation effect given that this patient went into diabetic remission approximately 22 months after treatment and the remission was sustained until euthanasia for a suspected nasal tumor. There was no evidence of tumor recurrence at the time of vision loss, suggesting that the vision loss could have been caused by radiation-induced optic neuropathy.
Our study supports a male sex predilection for the development of acromegaly in cats with approximately 80% of patients being male.
Although 43 patients (81%) were listed as domestic shorthairs, this designation is a default at our institution for mixed breed cats with short hair coats. Given this information, no breed predilection was identified in our study.
One cat developed generalized osteopenia based on interpretation of thoracic radiographs 2.5 years after SRT. Thoracic radiographs disclosed healed vertebral and sternebrae fractures as well as multiple healed rib fractures. Laboratory testing including serum vitamin D, calcium, and parathyroid hormone concentrations was performed at
Michigan State University and returned without abnormalities. The osteopenia was thought to be associated with the acromegaly. At the time of the radiography, the cat was suspected to have tumor progression, had come out of diabetic remission, and was exhibiting signs of polyuria, polydipsia, and polyphagia. This patient received SRT a second time, but was treated outside the time period to be included in the statistical analysis for our study. The pathogenesis of osteopenia in acromegaly is multifactorial, but is believed to be a result of GH hypersecretion causing high bone turnover, deterioration of bone microarchitecture, and high risk of vertebral fractures. 26 Although bone abnormalities have been noted in human patients with acromegaly, ours is the first study to report the development of acromegalic osteopathy in cats.
One cat underwent 2 treatments with SRT 39 months apart with the first protocol being 24Gy total over 3 fractions of 8Gy and the sec- conventionally fractionated radiotherapy, surgery followed by postoperative radiation therapy, and SRT to the pituitary gland and pharyngeal region. 30 These reports suggest a lower incidence of pituitary dysfunction in patients causing central endocrinopathies if they are treated with SRT. 30 Hormone function was disrupted in as few as 17% of patients treated with SRT when compared to 72-100% of patients treated with a fractionated protocol. 30, 31 In the previously described study, it also was determined that the pituitary gland is capable of secreting sufficient TSH to maintain euthyroidism, but its concentration is lower than in normal non-irradiated individuals. 32 Although these individuals continue to have low-normal concentrations of TSH, lthyroxine supplementation often is required for long term maintenance of euthyroidism. 30 Ours is the first study to report development of The primary limitations of our study are its retrospective nature and lack of consistent follow-up by the treating institution. Referring veterinarian records were reviewed for changes in physical examination findings and laboratory data after radiation, but the lack of consistency among clinicians was an important limitation. Necropsy results were available for 2 of the treated cats and provided encouraging information for successful treatment of the tumor, but the data would be stronger if more of the study population had undergone necropsy.
In conclusion, SRT is a safe and effective treatment for pituitary tumors causing acromegaly in cats. Acute radiation adverse effects are minimal in the treated population, mild in severity, limited in duration, and responsive to therapy. Late radiation effects include rare optic chiasm neuropathy, hypothyroidism, and potential for late stage neurologic progression. Based on the outcomes in our study, SRT should be considered for cats diagnosed with acromegaly.
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